Downmodulating an immune response with multivalent antibodies to PD-1
US6808710B1 · kind B1 · utility
278Cited by
1References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 23, 2000 |
| Grant date | Oct 26, 2004 |
| Priority date | — |
| Expiry date | Aug 23, 2020 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.